PTN
Palatin Technologies, Inc. [PTN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PTN Stock Summary
Top 10 Correlated ETFs
PTN
Top 10 Correlated Stocks
PTN
In the News
PTN Financial details
Company Rating
Neutral
Market Cap
30.98M
Income
-31.44M
Revenue
7.1M
Book val./share
-0.81
Cash/share
0.67
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-1.42
Forward P/E
-
PEG
0.45
P/S
6.61
P/B
-7.35
P/C
2.82
P/FCF
-1.55
Quick Ratio
0.51
Current Ratio
0.72
Debt / Equity
-0.07
LT Debt / Equity
-0.03
-
-
EPS (TTM)
-2.56
EPS next Y
-
EPS next Q
-
EPS this Y
-32.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-39.58%
Revenue Q/Q
-3.41%
EPS Q/Q
16.67%
-
-
-
-
SMA20
20.63%
SMA50
-55.01%
SMA100
-2.03%
Inst Own
0.01%
Inst Trans
0%
ROA
-222%
ROE
-472%
ROC
13.06%
Gross Margin
95%
Oper. Margin
-506%
Profit Margin
-411%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.43-5.65
52W High
-62.2%
52W Low
+89%
RSI
48.07
Rel Volume
0.25
Avg Volume
723.51K
Volume
180.6K
Perf Week
-9.13%
Perf Month
1.61%
Perf Quarter
-5.5%
Perf Half Y
7.39%
-
-
-
-
Beta
0.888
-
-
Volatility
0.05%, 0.16%
Prev Close
-0.53%
Price
1.89
Change
0.53%
PTN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 7.26 | 0.01 | -0.02 | 0.15 | 0.45 | |
| Net income per share | 4.31 | -2.38 | -3.55 | -3.75 | -2.53 | |
| Operating cash flow per share | -2.62 | 4.4 | -2.39 | -3.14 | -2.61 | |
| Free cash flow per share | -2.63 | 4.4 | -2.39 | -3.16 | -2.65 | |
| Cash per share | 5.24 | 8.83 | 6.35 | 3.14 | 1.01 | |
| Book value per share | 12.1 | 8.54 | 5.25 | 1.7 | 0.01 | |
| Tangible book value per share | 12.1 | 8.54 | 5.25 | 1.7 | 0.01 | |
| Share holders equity per share | 12.1 | 8.54 | 5.25 | 1.7 | 0.01 | |
| Interest debt per share | 0.09 | 0.14 | 0.13 | 0.12 | 0.09 | |
| Market cap | 226.36M | 119.69M | 144.36M | 66.81M | 22.87M | |
| Enterprise value | 183.18M | 38.1M | 85.5M | 38.02M | 15.93M | |
| P/E ratio | 6.33 | -5.35 | -4.3 | -1.87 | -0.83 | |
| Price to sales ratio | 3.75 | 1.01K | -765.42 | 45.49 | 4.71 | |
| POCF ratio | -10.39 | 2.9 | -6.37 | -2.23 | -0.8 | |
| PFCF ratio | -10.37 | 2.9 | -6.37 | -2.21 | -0.79 | |
| P/B Ratio | 2.25 | 1.49 | 2.91 | 4.11 | 170.57 | |
| PTB ratio | 2.25 | 1.49 | 2.91 | 4.11 | 170.57 | |
| EV to sales | 3.04 | 322.94 | -453.37 | 25.89 | 3.28 | |
| Enterprise value over EBITDA | 5.12 | -1.61 | -2.79 | -1.04 | -0.49 | |
| EV to operating cash flow | -8.41 | 0.92 | -3.78 | -1.27 | -0.56 | |
| EV to free cash flow | -8.4 | 0.92 | -3.77 | -1.26 | -0.55 | |
| Earnings yield | 0.16 | -0.19 | -0.23 | -0.54 | -1.2 | |
| Free cash flow yield | -0.1 | 0.34 | -0.16 | -0.45 | -1.26 | |
| Debt to equity | 0 | 0.02 | 0.03 | 0.07 | 7.84 | |
| Debt to assets | 0 | 0.01 | 0.02 | 0.03 | 0.06 | |
| Net debt to EBITDA | -1.21 | 3.46 | 1.92 | 0.79 | 0.21 | |
| Current ratio | 24.94 | 21.28 | 6.27 | 2.13 | 1.08 | |
| Interest coverage | 85.6 | -1.17K | -1.42K | -1.23K | 1.62K | |
| Income quality | -0.61 | -1.84 | 0.67 | 0.83 | 1.03 | |
| Dividend Yield | 0 | 0.02 | 0 | 0 | 0.01 | |
| Payout ratio | 0 | -0.11 | 0 | -0.01 | -0.01 | |
| Sales general and administrative to revenue | 0.16 | 82.77 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.25 | 118.31 | -68.54 | 14.52 | 4.66 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0.02 | |
| Capex to revenue | 0 | -0.53 | 0.03 | -0.18 | -0.09 | |
| Capex to depreciation | -0.62 | -0.98 | -0.11 | -2.06 | -1.5 | |
| Stock based compensation to revenue | 0.06 | 26.6 | -16.8 | 1.71 | 0.29 | |
| Graham number | 34.25 | 21.4 | 20.46 | 12 | 0.84 | |
| ROIC | 0.36 | -0.28 | -0.64 | -1.95 | -12.41 | |
| Return on tangible assets | 0.34 | -0.26 | -0.5 | -0.99 | -1.54 | |
| Graham Net | 10.18 | 8.31 | 4.67 | 1.25 | -0.4 | |
| Working capital | 100.23M | 79.66M | 55.4M | 18.34M | 1.19M | |
| Tangible asset value | 100.55M | 80.17M | 49.65M | 16.27M | 134.07K | |
| Net current asset value | 100.23M | 78.71M | 48.26M | 14.79M | -1.48M | |
| Invested capital | 0 | 0.02 | 0.03 | 0.07 | 7.84 | |
| Average receivables | 30.13M | 30.13M | 790.22K | 1.68M | 2.35M | |
| Average payables | 1.36M | 610.23K | 678.16K | 1.9M | 3.73M | |
| Average inventory | 74.87K | 74.87K | 581K | 1.05M | 735.24K | |
| Days sales outstanding | 364.79 | 0 | -3.06K | 442.44 | 219.27 | |
| Days payables outstanding | 12.4 | 18.71 | 1.58K | 5.3K | 3.75K | |
| Days of inventory on hand | 3.68 | 0 | 2.87K | 1.58K | 458.79 | |
| Receivables turnover | 1 | 0 | -0.12 | 0.82 | 1.66 | |
| Payables turnover | 29.43 | 19.51 | 0.23 | 0.07 | 0.1 | |
| Inventory turnover | 99.22 | 0 | 0.13 | 0.23 | 0.8 | |
| ROE | 0.36 | -0.28 | -0.68 | -2.2 | -205.42 | |
| Capex per share | 0 | -0.01 | 0 | -0.03 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.1 | 0.1 | 0.15 | 0.17 | 0.14 | |
| Net income per share | -0.13 | -0.61 | -0.91 | -0.48 | -0.56 | |
| Operating cash flow per share | -0.82 | -0.12 | -0.82 | -0.49 | -0.74 | |
| Free cash flow per share | -0.83 | -0.13 | -0.82 | -0.49 | -0.75 | |
| Cash per share | 1.96 | 1.72 | 0.94 | 0.45 | 0.67 | |
| Book value per share | 1.51 | 0.84 | 0.01 | -0.4 | -0.81 | |
| Tangible book value per share | 1.51 | 0.84 | 0.19 | -0.4 | -0.78 | |
| Share holders equity per share | 1.51 | 0.84 | 0.01 | -0.4 | -0.81 | |
| Interest debt per share | 0.09 | 0.07 | 0.09 | 0.08 | 0.06 | |
| Market cap | 27.66M | 31.44M | 24.62M | 18.38M | 56.11M | |
| Enterprise value | 7.39M | 12.61M | 17.68M | 13.79M | 47.45M | |
| P/E ratio | -4.85 | -1.12 | -0.57 | -0.78 | -1.79 | |
| Price to sales ratio | 26.94 | 26.29 | 13.97 | 8.73 | 27.58 | |
| POCF ratio | -3.13 | -22.32 | -2.56 | -3.11 | -5.36 | |
| PFCF ratio | -3.09 | -20.61 | -2.55 | -3.11 | -5.34 | |
| P/B Ratio | 1.69 | 3.28 | 183.65 | -3.79 | -4.93 | |
| PTB ratio | 1.69 | 3.28 | 183.65 | -3.79 | -4.93 | |
| EV to sales | 7.2 | 10.54 | 10.04 | 6.55 | 23.32 | |
| Enterprise value over EBITDA | -1.13 | -1.75 | -1.82 | -2.29 | -7.32 | |
| EV to operating cash flow | -0.84 | -8.95 | -1.84 | -2.33 | -4.53 | |
| EV to free cash flow | -0.83 | -8.27 | -1.83 | -2.33 | -4.51 | |
| Earnings yield | -0.05 | -0.22 | -0.44 | -0.32 | -0.14 | |
| Free cash flow yield | -0.32 | -0.05 | -0.39 | -0.32 | -0.19 | |
| Debt to equity | 0.06 | 0.08 | 7.84 | -0.19 | -0.07 | |
| Debt to assets | 0.03 | 0.03 | 0.06 | 0.08 | 0.06 | |
| Net debt to EBITDA | 3.1 | 2.61 | 0.71 | 0.76 | 1.34 | |
| Current ratio | 2.68 | 2.05 | 1.08 | 0.72 | 1.09 | |
| Interest coverage | -1.21K | -2.13K | -7.26K | -561.38 | -4.14K | |
| Income quality | 6.2 | 0.2 | 0.9 | 1 | 1.34 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.1 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 4.26 | 4.04 | 4.2 | 2.38 | 2.73 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.08 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.12 | -0.1 | -0.03 | 0 | -0.02 | |
| Capex to depreciation | -1.77 | -1.5 | -0.65 | 0 | -0.22 | |
| Stock based compensation to revenue | 0.35 | 0.33 | 0.13 | 0.19 | 0.27 | |
| Graham number | 2.12 | 3.4 | 0.48 | 2.08 | 3.18 | |
| ROIC | -0.08 | -0.64 | -4.84 | 2.05 | 0.65 | |
| Return on tangible assets | -0.04 | -0.27 | -0.6 | -0.52 | -0.58 | |
| Graham Net | 1 | 0.46 | -0.2 | -0.72 | -0.94 | |
| Working capital | 19.13M | 12.39M | 1.19M | -3.8M | 1.05M | |
| Tangible asset value | 16.34M | 9.59M | 2.22M | -4.89M | -10.96M | |
| Net current asset value | 14.92M | 8.22M | 599.35K | -6.33M | -12.27M | |
| Invested capital | 0.06 | 0.08 | 7.84 | -0.19 | -0.07 | |
| Average receivables | 4.25M | 4.09M | 2.31M | 2.13M | 1.85M | |
| Average payables | 2.3M | 1.8M | 3.54M | 3.29M | 1.93M | |
| Average inventory | 808.62K | 694.65K | 578.02K | 1.06M | 799.13K | |
| Days sales outstanding | 568.37 | 127.89 | 148.94 | 57.63 | 103.81 | |
| Days payables outstanding | 747.94 | 1.94K | 3.72K | 1.16K | 535.37 | |
| Days of inventory on hand | 692.29 | 438.76 | 455.05 | 817.66 | 0 | |
| Receivables turnover | 0.16 | 0.7 | 0.6 | 1.56 | 0.87 | |
| Payables turnover | 0.12 | 0.05 | 0.02 | 0.08 | 0.17 | |
| Inventory turnover | 0.13 | 0.21 | 0.2 | 0.11 | 0 | |
| ROE | -0.09 | -0.73 | -79.92 | 1.21 | 0.69 | |
| Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
PTN Frequently Asked Questions
What is Palatin Technologies, Inc. stock symbol ?
Palatin Technologies, Inc. is a US stock , located in Cranbury of Nj and trading under the symbol PTN
What is Palatin Technologies, Inc. stock quote today ?
Palatin Technologies, Inc. stock price is $1.89 today.
Is Palatin Technologies, Inc. stock public?
Yes, Palatin Technologies, Inc. is a publicly traded company.
Company Profile
- Volume Average 723.51K
- Market Capitalization 30.98M
- Employee 34
- CEO Dr. Carl Spana Ph.D.
- Headquarters Cranbury,NJ,US
- IPO Date 1997-10-15
-
Website
https://palatin.com 
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
